These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 24607293)

  • 61. Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine.
    Graham KA; Gu H; Lieberman JA; Harp JB; Perkins DO
    Am J Psychiatry; 2005 Sep; 162(9):1744-6. PubMed ID: 16135638
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study.
    Houston JP; Tohen M; Degenhardt EK; Jamal HH; Liu LL; Ketter TA
    J Clin Psychiatry; 2009 Nov; 70(11):1540-7. PubMed ID: 19778495
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind study.
    Smith RC; Jin H; Li C; Bark N; Shekhar A; Dwivedi S; Mortiere C; Lohr J; Hu Q; Davis JM
    Schizophr Res; 2013 Jan; 143(1):18-24. PubMed ID: 23200554
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Increased lean body mass as an early indicator of olanzapine-induced weight gain in healthy men.
    Daurignac E; Leonard KE; Dubovsky SL
    Int Clin Psychopharmacol; 2015 Jan; 30(1):23-8. PubMed ID: 25350366
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The effect of reboxetine co-administration with olanzapine on metabolic and endocrine profile in schizophrenia patients.
    Amrami-Weizman A; Maayan R; Gil-Ad I; Pashinian A; Fuchs C; Kotler M; Poyurovsky M
    Psychopharmacology (Berl); 2013 Nov; 230(1):23-7. PubMed ID: 23828160
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effect of Older vs Younger Age on Anthropometric and Metabolic Variables During Treatment of Psychotic Depression With Sertraline Plus Olanzapine: The STOP-PD II Study.
    Flint AJ; Rothschild AJ; Whyte EM; Alexopoulos GS; Mulsant BH; Marino P; Banerjee S; Pollari CD; Wu Y; Voineskos AN; Meyers BS;
    Am J Geriatr Psychiatry; 2021 Jul; 29(7):645-654. PubMed ID: 33268022
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [The stabilizing effect of dehydroepiandrosterone on clinical parameters of metabolic syndrome in patients with schizophrenia treated with olanzapine - a randomized, double-blind trial].
    Holka-Pokorska JA; Radzio R; Jarema M; Wichniak A
    Psychiatr Pol; 2015; 49(2):363-76. PubMed ID: 26093599
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial.
    Baptista T; Rangel N; Fernández V; Carrizo E; El Fakih Y; Uzcátegui E; Galeazzi T; Gutiérrez MA; Servigna M; Dávila A; Uzcátegui M; Serrano A; Connell L; Beaulieu S; de Baptista EA
    Schizophr Res; 2007 Jul; 93(1-3):99-108. PubMed ID: 17490862
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study.
    Hoffmann VP; Case M; Jacobson JG
    J Clin Psychiatry; 2012 Feb; 73(2):216-23. PubMed ID: 21672497
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors.
    Pérez-Iglesias R; Martínez-García O; Pardo-Garcia G; Amado JA; Garcia-Unzueta MT; Tabares-Seisdedos R; Crespo-Facorro B
    Int J Neuropsychopharmacol; 2014 Jan; 17(1):41-51. PubMed ID: 24103107
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination.
    Poyurovsky M; Fuchs C; Pashinian A; Levi A; Weizman R; Weizman A
    Psychopharmacology (Berl); 2013 Apr; 226(3):615-22. PubMed ID: 23239133
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Adjunctive telmisartan treatment on body metabolism in clozapine or olanzapine treated patients with schizophrenia: a randomized, double blind, placebo controlled trial.
    Fan X; Copeland P; Nawras S; Harrington A; Freudenreich O; Goff DC; Henderson DC
    Psychopharmacology (Berl); 2019 Jun; 236(6):1949-1957. PubMed ID: 30747254
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Effect of Topiramate on Drug Associated Weight Gain of Patients with Schizophrenia and Bipolar I Disorders: A Dose Ranging Randomized Trial].
    Talaeı A; Farıdhosseını F; Kazemı H; Fayyazı Bordbar MR; Rezaeı Ardanı A
    Turk Psikiyatri Derg; 2016; 27(2):0. PubMed ID: 27370059
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats.
    Raskind MA; Burke BL; Crites NJ; Tapp AM; Rasmussen DD
    Neuropsychopharmacology; 2007 Feb; 32(2):284-8. PubMed ID: 16710316
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Memantine Enhances the Effect of Olanzapine in Patients With Schizophrenia: A Randomized, Placebo-Controlled Study.
    Fakhri A; Pakseresht S; Haghdoost MR; Hekmatkhah N; Torkashvand M; Ghorbanzadeh B
    Acta Med Iran; 2016 Nov; 54(11):696-703. PubMed ID: 28033691
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study.
    Correll CU; Newcomer JW; Silverman B; DiPetrillo L; Graham C; Jiang Y; Du Y; Simmons A; Hopkinson C; McDonnell D; Kahn RS
    Am J Psychiatry; 2020 Dec; 177(12):1168-1178. PubMed ID: 32791894
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study.
    Poyurovsky M; Fuchs C; Pashinian A; Levi A; Faragian S; Maayan R; Gil-Ad I
    Psychopharmacology (Berl); 2007 Jun; 192(3):441-8. PubMed ID: 17310385
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The effect of zonisamide on antipsychotic-associated weight gain in patients with schizophrenia: a randomized, double-blind, placebo-controlled clinical trial.
    Ghanizadeh A; Nikseresht MS; Sahraian A
    Schizophr Res; 2013 Jun; 147(1):110-115. PubMed ID: 23583010
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Can an early weight management program (WMP) prevent olanzapine (OLZ)-induced disturbances in body weight, blood glucose and lipid metabolism? Twenty-four- and 48-week results from a 6-month randomized trial.
    Cordes J; Thünker J; Regenbrecht G; Zielasek J; Correll CU; Schmidt-Kraepelin C; Lange-Asschenfeldt C; Agelink MW; Kahl KG; Gaebel W; Klimke A; Hauner H
    World J Biol Psychiatry; 2014 Apr; 15(3):229-41. PubMed ID: 21745127
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers.
    Albaugh VL; Singareddy R; Mauger D; Lynch CJ
    PLoS One; 2011; 6(8):e22662. PubMed ID: 21857944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.